The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Pituitary Diseases

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Pituitary Diseases


Psychiatry related information on Pituitary Diseases

  • DESIGN: To further clarify this relationship, we used psychometric tests to quantify depression, apathy and typical psychosomatic complaints in patients with different types of pituitary disease and compared the results with measurements of the patients' widely varying GH status [6].

High impact information on Pituitary Diseases

  • As in all areas of clinical practice, strategies and protocols vary between centers, but most physicians experienced in the management of pituitary disease agree that GH is most appropriately begun at low doses, building up slowly to the final maintenance dose [7].
  • Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay [8].
  • These tests were undertaken in 23 patients considered GH deficient from extensive organic pituitary disease, and in 35 sex-matched normal subjects of similar age and body-mass index [9].
  • CONCLUSIONS: In the high-dose dexamethasone suppression test, the degree of suppression of urine free cortisol used for the diagnosis of pituitary disease is greater than that traditionally used for 17-hydroxysteroid excretion [10].
  • For each analysis, patients with pituitary disease were considered to be "diseased" and patients with nonpituitary disease were considered to be "non-diseased". The level of suppression that gave 100% specificity was determined for each steroid [10].

Chemical compound and disease context of Pituitary Diseases

  • The role of the low dose (1 microgram) ACTH stimulation test in the evaluation of patients with pituitary diseases was systematically assessed by relating its results to those obtained on gold standard tests of hypothalamo-pituitary-adrenal (HPA) reserve, such as insulin-induced hypoglycemia or a metyrapone challenge [11].
  • Twenty GHD elderly patients with a history of pituitary disease and a peak GH response to arginine stimulation of less than 3 ng/mL (15 men and 5 women; age, 61.1-83.4 yr) and 19 controls (12 men and 7 women; age, 60.8-87.5 yr) were studied [12].
  • Plasma pituitary hormone responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases [13].
  • LH and FSH responsiveness to intravenous gonadotropin-releasing hormone (GnRH) in children with hypothalamic or pituitary disorders: lack of effect of replacement therapy with human growth hormone [14].
  • To determine the prevalence of pituitary infundibular deviation or tilt as a normal variant, coronal magnetic resonance (MR) images of 50 patients who had been examined for reasons other than pituitary disease were evaluated retrospectively [15].

Biological context of Pituitary Diseases


Anatomical context of Pituitary Diseases


Gene context of Pituitary Diseases


Analytical, diagnostic and therapeutic context of Pituitary Diseases


  1. Discordant cortisol response to exogenous ACTH and insulin-induced hypoglycemia in patients with pituitary disease. Borst, G.C., Michenfelder, H.J., O'Brian, J.T. N. Engl. J. Med. (1982) [Pubmed]
  2. Somatotrophinomas in multiple endocrine neoplasia type 1: a review of clinical phenotype and insulin-like growth factor-1 levels in a large multiple endocrine neoplasia type 1 kindred. Burgess, J.R., Shepherd, J.J., Parameswaran, V., Hoffman, L., Greenaway, T.M. Am. J. Med. (1996) [Pubmed]
  3. Urinary excretion of cortisol in acromegaly. Lindholm, J., Kehlet, H., Riishede, J. J. Clin. Endocrinol. Metab. (1980) [Pubmed]
  4. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Vergès, B., Boureille, F., Goudet, P., Murat, A., Beckers, A., Sassolas, G., Cougard, P., Chambe, B., Montvernay, C., Calender, A. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  5. An apparent cluster of congenital hypopituitarism in central Massachusetts: magnetic resonance imaging and hormonal studies. Brown, R.S., Bhatia, V., Hayes, E. J. Clin. Endocrinol. Metab. (1991) [Pubmed]
  6. Growth hormone deficiency in pituitary disease: relationship to depression, apathy and somatic complaints. Zenker, S., Haverkamp, F., Klingmüller, D. Eur. J. Endocrinol. (2002) [Pubmed]
  7. Optimizing gh therapy in adults and children. Drake, W.M., Howell, S.J., Monson, J.P., Shalet, S.M. Endocr. Rev. (2001) [Pubmed]
  8. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. Furlanetto, R.W., Underwood, L.E., Van Wyk, J.J., D'Ercole, A.J. J. Clin. Invest. (1977) [Pubmed]
  9. Diagnosis of growth-hormone deficiency in adults. Hoffman, D.M., O'Sullivan, A.J., Baxter, R.C., Ho, K.K. Lancet (1994) [Pubmed]
  10. Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome. Flack, M.R., Oldfield, E.H., Cutler, G.B., Zweig, M.H., Malley, J.D., Chrousos, G.P., Loriaux, D.L., Nieman, L.K. Ann. Intern. Med. (1992) [Pubmed]
  11. The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary diseases. Tordjman, K., Jaffe, A., Grazas, N., Apter, C., Stern, N. J. Clin. Endocrinol. Metab. (1995) [Pubmed]
  12. Urinary growth hormone (GH), insulin-like growth factor I (IGF-I), and IGF-binding protein-3 measurements in the diagnosis of adult GH deficiency. Gill, M.S., Toogood, A.A., O'Neill, P.A., Thorner, M.O., Shalet, S.M., Clayton, P.E. J. Clin. Endocrinol. Metab. (1998) [Pubmed]
  13. Plasma pituitary hormone responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases. Demura, R., Suda, T., Wakabayashi, I., Yoshimura, M., Jibiki, K., Odagiri, E., Demura, H., Shizume, K. J. Clin. Endocrinol. Metab. (1981) [Pubmed]
  14. LH and FSH responsiveness to intravenous gonadotropin-releasing hormone (GnRH) in children with hypothalamic or pituitary disorders: lack of effect of replacement therapy with human growth hormone. Kelch, R.P., Markovs, M., Huss, J. J. Clin. Endocrinol. Metab. (1976) [Pubmed]
  15. Normal pituitary gland: coronal MR imaging of infundibular tilt. Ahmadi, H., Larsson, E.M., Jinkins, J.R. Radiology. (1990) [Pubmed]
  16. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. Fernholm, R., Bramnert, M., Hägg, E., Hilding, A., Baylink, D.J., Mohan, S., Thorén, M. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  17. Systemic toxicity of diphtheria toxin-related fragments (CRM26, CRM45), a hormone-toxin hybrid protein (TRH-CRM45), and ricin A. Bacha, P., Reichlin, S. Proc. Soc. Exp. Biol. Med. (1986) [Pubmed]
  18. Comparison of tests of stress-related cortisol secretion in pituitary disease (Clinical Endocrinology 1996:45:135-40). Jolobe, O.M. Clin. Endocrinol. (Oxf) (1997) [Pubmed]
  19. Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population. Hashimoto, K., Maruyama, H., Nishiyama, M., Asaba, K., Ikeda, Y., Takao, T., Iwasaki, Y., Kumon, Y., Suehiro, T., Tanimoto, N., Mizobuchi, M., Nakamura, T. Horm. Res. (2005) [Pubmed]
  20. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. Burgess, J.R., Shepherd, J.J., Parameswaran, V., Hoffman, L., Greenaway, T.M. J. Clin. Endocrinol. Metab. (1996) [Pubmed]
  21. Cerebrospinal fluid prolactin: a reflection of abnormal prolactin secretion in patients with pituitary tumors. Schroeder, L.L., Johnson, J.C., Malarkey, W.B. J. Clin. Endocrinol. Metab. (1976) [Pubmed]
  22. Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders. Brickman, J.M., Clements, M., Tyrell, R., McNay, D., Woods, K., Warner, J., Stewart, A., Beddington, R.S., Dattani, M. Development (2001) [Pubmed]
  23. Study of the multiple endocrine neoplasia type 1, growth hormone-releasing hormone receptor, Gs alpha, and Gi2 alpha genes in isolated familial acromegaly. Jorge, B.H., Agarwal, S.K., Lando, V.S., Salvatori, R., Barbero, R.R., Abelin, N., Levine, M.A., Marx, S.J., Toledo, S.P. J. Clin. Endocrinol. Metab. (2001) [Pubmed]
  24. A simple test for growth hormone deficiency in adults. Mahajan, T., Lightman, S.L. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  25. LHX3 transcription factor mutations associated with combined pituitary hormone deficiency impair the activation of pituitary target genes. Sloop, K.W., Parker, G.E., Hanna, K.R., Wright, H.A., Rhodes, S.J. Gene (2001) [Pubmed]
  26. Plasma adrenocorticotropin and cortisol responses to ovine corticotropin-releasing factor in patients with adrenocortical insufficiency due to hypothalamic and pituitary disorders. Tsukada, T., Nakai, Y., Koh, T., Tsujii, S., Inada, M., Nishikawa, M., Shinoda, H., Kawai, I., Takezawa, N., Imura, H. J. Clin. Endocrinol. Metab. (1984) [Pubmed]
  27. Growth hormone replacement therapy for growth hormone-deficient adults. Powrie, J., Weissberger, A., Sönksen, P. Drugs (1995) [Pubmed]
  28. Defining the normal cortisol response to the short Synacthen test: implications for the investigation of hypothalamic-pituitary disorders. Clark, P.M., Neylon, I., Raggatt, P.R., Sheppard, M.C., Stewart, P.M. Clin. Endocrinol. (Oxf) (1998) [Pubmed]
  29. Comparison of the diagnostic utility of the simplified and standard i.m. glucagon stimulation test (IMGST). Orme, S.M., Price, A., Weetman, A.P., Ross, R.J. Clin. Endocrinol. (Oxf) (1998) [Pubmed]
  30. In situ hybridization study of obesity-associated alteration in growth hormone mRNA levels. Ahmad, I., Steggles, A.W., Finkelstein, J.A. Int. J. Obes. Relat. Metab. Disord. (1992) [Pubmed]
WikiGenes - Universities